Get 20% Free Customization In This Report

Buy this report from - $3456

Global Etoricoxib Intermediate Market by Type of Manufacturing (In-House Manufacturing and Contract Manufacturing Organizations) and by Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases, and Other Applications) - Opportunities and Forecast, 2017-2023

Pharmaceuticals	LI_183639	Pages: NA	May 2018 \| 685 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that explicitly targets enzymes responsible for inflammation and pain namely cyclooxygenase-2 and COX-2. Some of the NSAIDs can be used in a single dose to treat various types of pain; it can also be used for post-surgical pains.

The growth of the global Etoricoxib market is driven by increase in prevalence of various chronic and acute diseases and surge in geriatric population. Moreover, rise in demand for cost effective anti-inflammatory drugs is anticipated to boost the growth of this market. However, stringent guidelines set by regulating authorities for pharmaceutical products is expected to hinder the market growth.

The global Etoricoxib intermediate market is segmented on the basis of type of manufacturing, indication, and geography. Based on type of manufacturing, it is bifurcated into in-house manufacturing and contract manufacturing organizations. Based on indication, the market is divided into rheumatoid arthritis, psoriatic arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Bayer Corporation, Novacap Inc., Abbott Laboratories, Pfizer Inc, Geri-Care Pharmaceuticals, Perrigo Company, Kopran Ltd., Merck Sharp & Dohme Corp., Sun Pharmaceutical Industries Ltd, GlaxoSmithKline, are provided in this report.

Key Benefits

The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework
It offers a quantitative analysis from 2017 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.

Global Etoricoxib Intermediate Market Key Segments:

By Type of Manufacturing

In-House Manufacturing
Contract Manufacturing Organizations

By Indication

Rheumatoid Arthritis
Psoriatic Arthritis
Osteoarthritis
Ankylosing Spondylitis
Chronic Low Back Pain
Acute Pain
Others

By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 ETORICOXIB MARKET, BY TYPE OF MANUFACTURING

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. IN-HOUSE MANUFACTURING

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. CONTRACT MANUFACTURING ORGANIZATIONS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

Chapter: 5 ETORICOXIB MARKET, BY INDICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. RHEUMATOID ARTHRITIS

5.2.1. Market size and forecast

5.3. PSORIATIC ARTHRITIS

5.3.1. Market size and forecast

5.4. OSTEOARTHRITIS

5.4.1. Market size and forecast

5.5. ANKYLOSING SPONDYLITIS

5.5.1. Market size and forecast

5.6. CHRONIC LOW BACK PAIN

5.6.1. Market size and forecast

5.7. ACUTE PAIN

5.7.1. Market size and forecast

5.8. OTHERS

5.8.1. Market size and forecast

Chapter: 6 ETORICOXIB MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast

Chapter: 7 COMPANY PROFILES

7.1. BAYER CORPORATION

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. NOVACAP INC.

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. ABBOTT LABORATORIES

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. PFIZER INC

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. GERI-CARE PHARMACEUTICALS

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. PERRIGO COMPANY

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. KOPRAN LTD.

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. MERCK SHARP & DOHME CORP.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. SUN PHARMACEUTICAL INDUSTRIES LTD

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. GLAXOSMITHKLINE

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Shopping Cart is Empty..

Your Shopping Cart Is Empty

Global Etoricoxib Intermediate Market by Type of Manufacturing (In-House Manufacturing and Contract Manufacturing Organizations) and by Application (Oncology, Chronic and Autoimmune Diseases, Blood Disorders, Infectious Diseases, and Other Applications) - Opportunities and Forecast, 2017-2023